Achieve Life Sciences

Contributing Author

Recent Articles by Achieve Life Sciences

11 hours	Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program ACHV GlobeNewswire
Nov-03	Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation ACHV GlobeNewswire
Oct-29	Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025 ACHV GlobeNewswire
Oct-20	Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer ACHV GlobeNewswire
Oct-17	Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation ACHV GlobeNewswire
Oct-02	Achieve Life Sciences Announces Granting of New Hire Inducement Awards ACHV GlobeNewswire
Sep-22	Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD ACHV GlobeNewswire
Sep-18	Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer ACHV GlobeNewswire
Sep-11	Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer ACHV GlobeNewswire
Sep-03	Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation ACHV GlobeNewswire
Sep-02	Achieve Life Sciences Announces Participation at Upcoming Investor Conferences ACHV GlobeNewswire
Aug-07	Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program ACHV GlobeNewswire
Jul-29	Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference ACHV GlobeNewswire
Jul-24	Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025 ACHV GlobeNewswire
Jun-30	Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Proposed Underwritten Public Offering ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades ACHV GlobeNewswire
Jun-26	Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation ACHV GlobeNewswire
May-28	Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference ACHV GlobeNewswire
May-20	Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake ACHV GlobeNewswire
May-13	Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program ACHV GlobeNewswire
May-06	Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025 ACHV GlobeNewswire

Achieve Life Sciences

Recent Articles by Achieve Life Sciences

Upgrade your FINVIZ experience